Loading...
Loading...
Medical imaging (X-ray, CT, MRI), electronic health records, clinical trials, ECG/EEG, pathology
12,704 datasets
A dataset for Alzheimer's disease prediction containing cognitive, neuroimaging, genetic, and demographic features. It includes three patient classes: Cognitively Normal (CN), Mild Cognitive Impairment (MCI), and AD. The data was used in a study by Emad Al-anbari, last updated on 2026-04-20.
The Alzheimer's Disease Prediction of Longitudinal Evolution (TADPOLE) dataset contains cognitive, neuroimaging, genetic, and demographic data for predicting Alzheimer's progression. It includes three diagnostic classes: Cognitively Normal (CN), Mild Cognitive Impairment (MCI), and AD. The dataset, shared by Emad Al-anbari on figshare under CC-BY-4.0, is a 5.5 KB XLS file last updated in April 2026.
A retrospective observational study of 667 orthognathic surgery cases from 632 patients treated at a single department between 2014 and 2024. The dataset, created by Takuma Watanabe, examines associations between clinical variables and postoperative nausea and vomiting (PONV). It includes patient demographics, surgical details, and outcomes, with descriptive statistics and logistic regression results provided.
Nepal-based clinical study of 75 patients with Gilbert Syndrome, analyzing correlations between UGT1A1 genotypes and biochemical parameters. The dataset includes genetic test results, bilirubin levels, and hematological data collected prospectively from July to November 2025, with retrospective medical records dating back to January 2021. It was authored by Pragya Gautam Ghimire and shared under a CC-BY-4.0 license.
Raymond Oppong's study, last updated in April 2026, presents a model-based cost-utility analysis of the Biofire Film Array Respiratory Panel RP 2.1+ test for patients with chronic obstructive pulmonary disease (COPD). The 5.5 KB Excel file contains results from a 40-year healthcare perspective model, evaluating the test's cost-effectiveness and the potential impact of accounting for antimicrobial resistance (AMR) costs. The analysis indicates the test is cost-saving, with potential annual savings estimated between £118 million and £18.6 billion.
A 40-year model-based cost-utility analysis evaluating the Biofire Film Array Respiratory Panel RP 2.1+ test for COPD patients. The dataset, authored by Raymond Oppong and last updated in April 2026, contains results indicating the test is cost-saving and more effective, with potential annual savings ranging between £118 million and £18.6 billion.
A model-based cost-utility analysis evaluating the Biofire Film Array Respiratory Panel RP 2.1+ test for patients with chronic obstructive pulmonary disease. The dataset contains results from a 40-year healthcare perspective model, including cost and quality-adjusted life year (QALY) differences. It was authored by Raymond Oppong and last updated on 2026-04-27.
5.5 KB of model-based cost-utility analysis results evaluating the Biofire Film Array Respiratory Panel RP 2.1+ test for COPD patients. The data, authored by Raymond Oppong and last updated in April 2026, indicates a 70% chance the test is cost-effective and could generate annual savings between £118 million and £18.6 billion. The analysis includes two approaches for accounting for antimicrobial resistance costs.
A 40-year model-based cost-utility analysis evaluating the Biofire Film Array Respiratory Panel RP 2.1+ test for COPD patients. The dataset, created by Raymond Oppong and last updated in April 2026, contains results indicating the test is cost-saving and more effective, with potential annual savings estimated between £118 million and £18.6 billion.
5.5 KB of model-based cost-utility analysis data evaluating a respiratory panel test for COPD patients. The dataset, authored by Raymond Oppong and last updated in April 2026, contains results from a 40-year healthcare perspective model, indicating the test is cost-saving with a 70% chance of being cost-effective. Potential annual savings from adopting the test are estimated between £118 million and £18.6 billion.
A 9.5 KB Excel file contains model-based cost-utility analysis results for a diagnostic test in chronic obstructive pulmonary disease (COPD) management. The study by Raymond Oppong, published on figshare in April 2026, evaluates the Biofire Film Array Respiratory Panel RP 2.1+ test over a 40-year healthcare perspective. Results indicate the test is cost-saving, with potential annual savings estimated between £118 million and £18.6 billion.
Raymond Oppong's dataset contains results from a model-based cost-utility analysis of the Biofire Film Array Respiratory Panel RP 2.1+ test for patients with chronic obstructive pulmonary disease (COPD). The analysis, conducted from a healthcare perspective over a 40-year horizon, evaluates the test's cost-effectiveness and potential savings related to antimicrobial resistance (AMR). The dataset, last updated on 2026-04 27, is a 627.2 KB XLSX file.
Nova Scotia Health Authority and IWK hand hygiene rates for healthcare workers, collected quarterly by trained auditors. The dataset reports rates for hand cleaning before and after contact with patients or their environment, as published by the Department of Health and Wellness. Data fields include Year, Quarter, Zone, Before Initial Contact, and After Contact.
Ilaria Valentini's 2026 study provides a partitioned survival model evaluating the cost-effectiveness of lorlatinib as first-line treatment for ALK-positive advanced non-small cell lung cancer in Italy. The model uses clinical data from the CROWN trial and network meta-analysis, with costs in 2026 euros and outcomes measured in life-years and quality-adjusted life-years. The base-case analysis found lorlatinib to be dominant, providing higher benefits at lower costs compared to alectinib.
Supplementary Information for a study of a family where 11 members were affected by hyperinsulinemic hypoglycemia, diabetes, or both. The research identified a heterozygous MAFA variant in 6 family members and used immunohistochemistry to examine pancreatic tissue. The dataset was authored by Evgenia Globa and is licensed under CC-BY-4.0.
Supplemental data from a randomized controlled trial investigating skeletal muscle metabolism in critically ill patients. The dataset likely contains measurements of mitochondrial function, ATP, glycogen, lactate, and gene expression from patients during and up to 6 months after ICU admission, compared to elective surgery and muscle disuse control groups. The data was published by Tom S.O. Jameson in 2026 to accompany a study in the American Journal of Physiology-Endocrinology and Metabolism.
225 patients with non-melanoma skin cancer were treated between 2010 and 2020 to compare surgical methods. Gerlind Schneider's study found a 4.9% overall final positive resection margin rate, with all cases occurring in the one-step surgery group. The median follow-up time was 17.5 months, with 33 local recurrences observed.
A 2026 figshare document presents two clinical case reports on a 1-year follow-up of patients with macular neovascularization secondary to angioid streaks. The report, authored by figshare admin karger, details the treatment outcomes using intravitreal faricimab under a treat-and-extend protocol. The supplementary material is a 215.3 KB DOCX file.
94 neonates with moderate to severe hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia were studied from March 2024 to March 2025. The data, shared by Weihong Yue on figshare, compares early versus delayed enteral feeding groups on outcomes like gastrointestinal adverse events and hospitalization costs. No significant difference in gastrointestinal adverse events was found between groups, but early feeding was associated with shorter parenteral nutrition duration and reduced costs.
159 patient records from a multicenter double-blinded randomized controlled trial conducted across three tertiary hospitals in China. The study evaluated whether transcutaneous electrical acupoint stimulation (TEAS) added to antiemetic therapy reduces postoperative nausea and vomiting (PONV) within 24 hours after hepatectomy. The dataset was authored by Shan He and last updated on 2026-04-20.